RecruitingPhase 1NCT05418088
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Studying B-cell prolymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sumithira Vasu
- Principal Investigator
- Sumithira Vasu, MDOhio State University Comprehensive Cancer Center
- Intervention
- Anti-CD19/CD20/CD22 CAR T-Cells(biological)
- Enrollment
- 54 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2022 – 2026
Study locations (2)
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05418088 on ClinicalTrials.govOther trials for B-cell prolymphocytic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT02153580Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaCity of Hope Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT02007044Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT01589302PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaKami Maddocks, MD